Unknown

Dataset Information

0

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.


ABSTRACT: BACKGROUND:Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma. METHODS:A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma treated with eribulin. Eligible patients were between 12 and 50 years of age, had measurable tumor, and met standard organ function requirements. Patients were given eribulin 1.4 mg/m2 /dose on days 1 and 8 of each 3-week cycle for up to 24 months if there was no progressive disease. Response to therapy was assessed using RECIST 1.1 criteria after cycles 2 and 5 and every fourth cycle thereafter. RESULTS:Nineteen patients enrolled on the AOST1322 study. The median age of enrollment was 16 years (range, 12-25 years). Twelve patients were male and seven female. Eribulin was well tolerated, with neutropenia identified as the most common toxicity. The median progression-free survival was 38 days and no patients reached the four-month time point without progression. No objective responses were seen in any patient. CONCLUSION:This study rapidly assessed the clinical activity of a novel agent in this patient population. Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months.

SUBMITTER: Isakoff MS 

PROVIDER: S-EPMC6501793 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

Isakoff Michael S MS   Goldsby Robert R   Villaluna Doojduen D   Krailo Mark D MD   Hingorani Pooja P   Collier Anderson A   Morris Carol D CD   Kolb E Anders EA   Doski John J JJ   Womer Richard B RB   Gorlick Richard R   Janeway Katherine A KA  

Pediatric blood & cancer 20181030 2


<h4>Background</h4>Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma.<h4>Methods</h4>A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma trea  ...[more]

Similar Datasets

| S-EPMC5012712 | biostudies-literature
| S-EPMC4501773 | biostudies-literature
| S-EPMC6897379 | biostudies-literature
| S-EPMC6952063 | biostudies-literature
| S-EPMC6019176 | biostudies-literature
| S-EPMC9631806 | biostudies-literature
| S-EPMC4944867 | biostudies-literature
| S-EPMC4605828 | biostudies-literature
| S-EPMC3779033 | biostudies-literature
| S-EPMC6249072 | biostudies-literature